Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

In the months after their transplants, the patients in the study were treated with immunosuppressive drugs, but four out of five of them were able to discontinue those drugs between 9 and 14 months after surgery, and their new kidneys have been functioning well in the years since.

“I think it’s quite exciting,” Magee says. “It shows what’s possible.”

The researchers’ approach could make transplants more feasible for people whose immune systems are already compromised by conditions like HIV, according to Yasir Qazi, medical director of the kidney and pancreas transplant program at the University of Southern California. (Qazi was not involved in the work.) Sykes says that the approach could potentially be used to treat autoimmune diseases such as type 1 diabetes. “It could have huge benefits,” she says.

Although immunosuppressive drugs have revolutionized transplant medicine, they can increase the risk of cancer and heart disease. “Immunosuppression is great, because it makes kidneys work, but it’s bad because it has lots of side effects,” Magee says. “Some people say that in many ways, you’re trading one disease for another. You still have to take lots of medicine and see a doctor.”

The protocol developed by Sykes and her colleagues initially requires heavier drug treatment than that required with the standard kidney-transplant procedure, to allow the recipient’s body to accept donated bone marrow as well as a donated kidney. But, she points out, the patient is only on the drugs for a limited time.

2 comments. Share your thoughts »

Credit: AJPhoto / Photo Researchers, Inc.

Tagged: Biomedicine, disease, transplant

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me